Citi lowered the firm’s price target on Syndax (SNDX) to $42 from $45 and keeps a Buy rating on the shares post the Q4 report. The firm says the stock’s “non-reaction” to Syndax’s first print for Revuforj that handily beat consensus reflects the lack of incremental buyers who see relapsed or refractory KMT2A-rearranged leukemia as too narrow despite first-to-market advantage and early strong commercial execution. Citi believes it may take time for the NPM1 launch to “move the needle.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNDX:
- Promising Outlook for Syndax Pharmaceuticals: Buy Rating Supported by Revuforj Launch and Strategic Positioning
- Syndax Pharmaceuticals: Navigating Revenue Growth Amidst Regulatory and Market Challenges
- Syndax Pharmaceuticals Reports 2024 Financial Results
- Syndax Pharmaceuticals’ Earnings Call Highlights Key Milestones
- Syndax price target lowered to $29 from $36 at B. Riley